Switch to
More onapp

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
SmallcapWith a market cap of ₹12,191 cr, stock is ranked 311
Low RiskStock is 1.71x as volatile as Nifty
428.652.05 (-0.48%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹12,191 cr, stock is ranked 311
Low RiskStock is 1.71x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
12.95
PB RatioPB Ratio
1.29
Dividend YieldDiv. Yield
0.58%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

56%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

Brands

Glenmark Pharma

Pharmaceutical company

Investor PresentationView older 

Nov 17, 2022

PDF
View Older Presentations

Brands

Glenmark Pharma

Pharmaceutical company

Financial TrendFinancial statements 

201920202021202210.2410.8311.0412.470.920.780.970.94
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 25, 2022

Glenmark Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Glenmark Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

General updates 
Announced OnNov 23, 2022

Update on the US FDA inspection of Glenmark¬タルs Goa manufacturing facility | Download

Update on the US FDA inspection of Glenmark¬タルs Goa manufacturing facility | Download

Cash Dividend 
Ex. DateSep 12, 2022

Final • Div/Share: ₹ 2.5

See all events